Aquestive received an upfront fee and may earn milestone payments and royalties. It will also make and supply the product, though future payments depend on approvals and sales.
The license adds cash now and possible payments if regulators approve the product and sales grow. Aquestive also keeps a long-term role making and supplying it. The main limit is that approval and sales milestones are not assured.
Eton gained exclusive U.S. sales rights to LIBERVANT, but must pay an upfront fee, possible milestones, and royalties. Approval and sales remain uncertain, so the filing does not show whether the rights will pay off.
Follow Aquestive Therapeutics, Inc. (AQST) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AQST